New: Fluorescent 3D tumor microtissues
In May, InSphero, in collaboration with Sirion Biotech, Germany, launched a new product family that makes oncology drug testing using 3D microtissues much easier: our assay-ready, fluorescent 3D microtissues can be directly read out using fluorescence plate readers. More information on this new product here.
Fluorescent tumor co-culture of HCT116 (green) and NIH3T3 fibroblast cells (red)
New application note with Tecan: Analyzing biological drug effects in 3D
InSphero workshop in Copenhagen, Denmark, Feb 2012
3D cell culture literature picks – May 2012
Our applications team has reviewed a small selection of current 3D-cell-culture journal papers this month to keep you up-to-date about recent developments in 3D.
New USA Sales Manager
With InSphero's business growing rapidly in the USA, Davina Heller has joined the company as our new USA Sales Manager. She resides in San Diego and covers the Western and Midwestern states. Read more here.
Meet the InSphero team at upcoming fairs, conferences and workshops to learn how scaffold-free organotypic 3D microtissues, and 3D optimized assays, accelerate the process of drug discovery and development.
To arrange a meeting or a webinar, or register for a workshop please send us an E-mail.
InSphero is a leading supplier of organotypic, biological in-vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, currently counts 6 of the top ten global pharmaceutical and cosmetics companies as customers, and is helping them implement the company’s patent-pending microtissue technology in their development work-flow. InSphero’s 3D microtissues are scaffold free, highly reproducible and delivered in an automation-compatible 96-well format to replace conventional 2D cell assays for better biological relevance and predictivity. The 3D cancer microtissues reflect tumor physiology and are used routinely for screening. For toxicology and metabolics applications, rat and human 3D liver microtissues predict even rare cases of idiosyncratic toxicology and remain viable for more than 5 weeks for chronic studies. InSphero’s off-the-shelf portfolio of assay-ready microtissues is complemented by custom-made 3D microtissues with a development time of 4-6 weeks and production turnaround of less than 10 days.
InSphero is a spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich. The company was recognized for its scientific and commercial achievements with a number of awards, including the VentureKick award, Heuberger Entrepreneurial Award, CTIstartup certification and the SLAS New Product Award (NPA) 2011 Designation. InSphero is also officially certified to the ISO 9001:2008 standard for its Quality Management System.